NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

Followed 117 Times Searched 709 Times

$167.11

+4.42 (+2.72 %)

(As of 04/20/2021 12:40 PM ET)

Add

Compare

Today's Range

$160.81

Now: $167.11▼

$167.47

50-Day Range

$153.07

MA: $160.83▼

$166.04

52-Week Range

$133.65

Now: $167.11▼

$173.65

Volume469,000 shs

Average Volume8.23 million shs

Market Capitalization$439.95 billion

P/E Ratio26.28

Dividend Yield2.49%

Beta0.7

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:JNJ

Previous Symbol

CUSIP47816010

CIK200406

Webwww.jnj.com

Phone732-524-0400

Employees134,500

Year Founded1886

Debt

Debt-to-Equity Ratio0.51

Current Ratio1.48

Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio26.28

Forward P/E Ratio20.91

P/E Growth3.06

Sales & Book Value

Annual Sales$82.06 billion

Price / Sales5.36

Cash Flow$12.19 per share

Price / Cash Flow13.71

Book Value$22.60 per share

Price / Book7.39

Profitability

EPS (Most Recent Fiscal Year)$8.68

Net Income$15.12 billion

Net Margins21.01%

Return on Equity34.64%

Return on Assets13.40%

Miscellaneous

Outstanding Shares2,632,707,000

Market Cap$439.95 billion

Next Earnings Date4/20/2021 (Confirmed)

OptionableOptionable

Headlines

Johnson & Johnson Q1 profit, sales jump, beat Street views
April 20, 2021 | marketbeat.com

EU agency links J&J shot to rare clots, says odds favor use
April 20, 2021 | marketbeat.com

The Latest: Amid surge, India PM calls off visit to Portugal
April 20, 2021 | marketbeat.com

EU regulator finds link between J&J shot and blood clots
April 20, 2021 | marketbeat.com

Dividend King Johnson & Johnson Is Ready To Scale New Highs
April 20, 2021 | marketbeat.com

The Latest: Osaka seeks tougher virus state of emergency
April 20, 2021 | marketbeat.com

EU regulator prepares to issue advice on use of J&J vaccine
April 20, 2021 | marketbeat.com

Many global stocks lower after Wall St. decline
April 20, 2021 | marketbeat.com

Asian stock markets mixed after Wall St decline
April 20, 2021 | marketbeat.com

The Latest: Schools reopen in Mexico's Campeche state
April 19, 2021 | marketbeat.com

Johnson & Johnson Shows Health Economy Is Nearing Full Strength
April 20, 2021 | wsj.com

Johnson & Johnson (JNJ) Beats Q1 Earnings and Revenue Estimates
April 20, 2021 | msn.com

Johnson & Johnson Q1 Results Top Estimates
April 20, 2021 | nasdaq.com

Warren Buffett Owns These 5 Dividend Aristocrats. Should You?
April 20, 2021 | finance.yahoo.com

Johnson & Johnson Just Reported Earnings. This Number Is Critical.
April 20, 2021 | finance.yahoo.com

J&J reports $100 million in vaccine sales as results top forecasts
April 20, 2021 | finance.yahoo.com

Johnson & Johnson 2021 Q1 - Results - Earnings Call Presentation
April 20, 2021 | seekingalpha.com

California counties seek billions from drugmakers in opioid trial
April 20, 2021 | ft.com

Philippines approves emergency use of J&J, Bharat BiotechCOVID-19 vaccines
April 19, 2021 | finance.yahoo.com

Should You Buy Johnson & Johnson (JNJ) Ahead of Earnings?
April 19, 2021 | in.finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

2.52 out of 5 stars

Medical Sector

3rd out of 2,018 stocks

Pharmaceutical Preparations Industry

2nd out of 772 stocks

2.4 Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $182.62, Johnson & Johnson has a forecasted upside of 9.6% from its current price of $166.61.
Amount of Analyst Coverage
Johnson & Johnson has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Johnson & Johnson has received 1,022 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Johnson & Johnson has received 1,050 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Johnson & Johnson has received 50.68% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote “Outperform” if you believe JNJ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 2.49%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 59 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 46.54%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 45.44% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.27% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
67.25% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 11.26% in the coming year, from $7.99 to $8.89 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 26.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.64.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 26.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.59.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 3.06. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$167.11

+4.42 (+2.72 %)

(As of 04/20/2021 12:40 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

Is Johnson & Johnson a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Johnson & Johnson stock.
View analyst ratings for Johnson & Johnson or view top-rated stocks.

What stocks does MarketBeat like better than Johnson & Johnson?

Wall Street analysts have given Johnson & Johnson a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Johnson & Johnson wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, April 20th 2021.
View our earnings forecast for Johnson & Johnson.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, April, 20th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.34 by $0.25. The business earned $22.30 billion during the quarter, compared to analyst estimates of $22 billion. Johnson & Johnson had a net margin of 21.01% and a trailing twelve-month return on equity of 34.64%. Johnson & Johnson's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.30 earnings per share.
View Johnson & Johnson's earnings history.

How has Johnson & Johnson's stock been impacted by COVID-19 (Coronavirus)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, JNJ stock has increased by 26.6% and is now trading at $166.84.
View which stocks have been most impacted by COVID-19.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Tuesday, April 20th. Shareholders of record on Tuesday, May 25th will be given a dividend of $1.06 per share on Tuesday, June 8th. This represents a $4.24 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Monday, May 24th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.01.
View Johnson & Johnson's dividend history.

Is Johnson & Johnson a good dividend stock?

Johnson & Johnson pays an annual dividend of $4.04 per share and currently has a dividend yield of 2.49%. Johnson & Johnson has been increasing its dividend for 59 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Johnson & Johnson is 46.54%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 45.44% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.
View Johnson & Johnson's dividend history.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY21 earnings guidance on Tuesday, April, 20th. The company provided EPS guidance of $9.42-$9.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.52. The company issued revenue guidance of $90.6-$91.6 billion, compared to the consensus revenue estimate of $92.03 billion.

What price target have analysts set for JNJ?

14 Wall Street analysts have issued 12-month price objectives for Johnson & Johnson's stock. Their forecasts range from $160.00 to $200.00. On average, they expect Johnson & Johnson's share price to reach $182.62 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts' price targets for Johnson & Johnson or view top-rated stocks among Wall Street analysts.

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:

Mr. Alex Gorsky, Chairman & CEO (Age 61, Pay $5.58M) (LinkedIn Profile)
Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 54, Pay $2.01M) (LinkedIn Profile)
Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 59, Pay $3.68M) (LinkedIn Profile)
Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 58, Pay $3.35M)
Ms. Jennifer L. Taubert, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 57, Pay $2.04M) (LinkedIn Profile)
Mr. Robert J. Decker Jr., Controller & Chief Accounting Officer (Age 49)
Mr. James Swanson, Exec. VP & Global CIO
Mr. Christopher DelOrefice, VP of Investor Relations
Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 62) (LinkedIn Profile)
Ms. Ashley Watson, Chief Compliance Officer (Age 52) (LinkedIn Profile)

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson CEO Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among Johnson & Johnson's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Johnson & Johnson's key competitors?

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of JNJ's competitors.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), The Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), The Procter & Gamble (PG) and AbbVie (ABBV).

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST (0.08%), DnB Asset Management AS (0.06%), Royal London Asset Management Ltd. (0.05%), Retirement Systems of Alabama (0.05%), Capital Wealth Planning LLC (0.04%) and Welch & Forbes LLC (0.03%). Company insiders that own Johnson & Johnson stock include Ashley Mcevoy, Hubert Joly, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed and William D Perez.
View institutional ownership trends for Johnson & Johnson.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Royal London Asset Management Ltd., DnB Asset Management AS, Hexavest Inc., Windward Capital Management Co. CA, FDx Advisors Inc., Country Trust Bank, and Gateway Investment Advisers LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Ashley Mcevoy, Kathryn E Wengel, and Michael E Sneed.
View insider buying and selling activity for Johnson & Johnson or view top insider-selling stocks.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was bought by a variety of institutional investors in the last quarter, including Capital Wealth Planning LLC, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST, Roffman Miller Associates Inc. PA, International Assets Investment Management LLC, Everence Capital Management Inc., Saratoga Research & Investment Management, Hennessy Advisors Inc., and Tandem Investment Advisors Inc.. Company insiders that have bought Johnson & Johnson stock in the last two years include Hubert Joly, Marillyn A Hewson, and William D Perez.
View insider buying and selling activity for Johnson & Johnson or or view top insider-buying stocks.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $166.84.

How much money does Johnson & Johnson make?

Johnson & Johnson has a market capitalization of $439.24 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis.

How many employees does Johnson & Johnson have?

Johnson & Johnson employs 134,500 workers across the globe.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiares of Johnson & Johnson: ALZA Corporation, Abott Medical Optics, Acclarent, Actelion Pharmaceuticals, Advanced Sterilization Products Services Inc., Alios BioPharma, Animas Corporation, Apsis, Apsis Germany GmbH, Aragon Pharmaceuticals, Auris Health, Beijing Dabao Cosmetics Co., Berna Rhein B.V., BioMedical Enterprises, Biosense Webster, Biosense Webster (Israel) Ltd., CNA Development GmbH, Centocor Research & Development, Ci:z Holdings, Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Finance Unlimited Company, Cilag Pharmaceuticals GmbH, Codman & Shurtleff, Coherex Medical, Conor MedSystems, Cordis Financing Corporation, Cordis LLC, Cordis de Mexico, Covagen AG, Crucell N.V., DePuy France, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mitek, DePuy Orthopaedics, DePuy Products, DePuy Spine, DePuy Synthes, DePuy Synthes Apollo Limited, DePuy Synthes Eos Limited, DePuy Synthes Gorgan Limited, DePuy Synthes Jason Limited, DePuy Synthes Leto S.A.R.L., DePuy Synthes Products, DePuy Synthes Sales, Diabetes Diagnostics, EES, Ethicon, Ethicon Endo-Surgery, Ethicon Endo-Surgery LLC, Ethicon Holding Sarl, Ethicon Ireland, Ethicon LLC, Ethicon PR Holdings, Ethicon US, Ethicon Women's Health & Urology Sarl, Ethnor del Istmo, FMS Future Medical System SA, GMED Healthcare BVBA, Global Investment Participation B.V., J&J Holdings (Nevada), J-C Health Care Ltd., J.C. General Services CVBA, JJC Acquisition Company B.V., JJHC, JNJ International Investment LLC, JOM Pharmaceutical Services, Janssen, Janssen Biologics (Ireland), Janssen Biologics B.V., Janssen Biotech, Janssen Cilag Farmaceutica S.A., Janssen Egypt, Janssen Global Services, Janssen Infectious Diseases-Diagnostics BVBA, Janssen Irish Finance Company UC, Janssen Korea Ltd., Janssen Oncology, Janssen Ortho LLC, Janssen Pharmaceutica NV, Janssen Pharmaceutical, Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceuticals, Janssen Products, Janssen R&D Ireland, Janssen Research & Development, Janssen Sciences Ireland UC, Janssen Scientific Affairs, Janssen Supply Group, Janssen Vaccines & Prevention B.V., Janssen Vaccines AG, Janssen Vaccines Corp., Janssen de Mexico, Janssen-Cilag, Janssen-Cilag A/S, Janssen-Cilag AB, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica, Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag Kft., Janssen-Cilag Limited, Janssen-Cilag Limited (UK), Janssen-Cilag Manufacturing, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Pty Ltd, Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag S.p.A., Janssen-Cilag de Mexico, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (China) Ltd., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines), Johnson & Johnson (Proprietary) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson AB, Johnson & Johnson AG, Johnson & Johnson Belgium Finance Company, Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson European Treasury Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Group Holdings GmbH, Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International Financial Services Company, Johnson & Johnson Japan Inc., Johnson & Johnson K.K., Johnson & Johnson Korea, Johnson & Johnson Korea Selling & Distribution Limited Liability Company, Johnson & Johnson LLC, Johnson & Johnson Limitada, Johnson & Johnson Limited, Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Limited, Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico, Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty. Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pty. Limited, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.p.A., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services, Johnson & Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, Johnson & Johnson Swiss Finance Company Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care, Johnson & Johnson Vision Care (Ireland), Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Mexico, Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export & Import LLC, Johnson & Johnson s.r.o., Johnson & Johnson s.r.o. (Slovakia), Latam International Investment Company, Latam Properties Holdings, LifeScan, LifeScan Products, LifeScan Scotland Limited, Lifescan (France), McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Nutritionals, McNeil Products Limited, McNeil Sweden AB, Medical Devices & Diagnostics Global Services, Medos International Sarl, Medos Sarl, Mentor B.V., Mentor Holding PP, Mentor Medical Systems B.V., Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Pharmaceuticals, NeoStrata Company Inc., NeuWave Medical, Novira Therapeutics, OBTECH Medical Sarl, OMJ Ireland, OMJ PR Holdings, Omrix Biopharmaceuticals Ltd., Ortho Biologics LLC, Ortho Biotech Holding LLC, Orthotaxy, PMC Holdings G.K., PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals, Penta Pty. Limited, Pulsar Vascular, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Shanghai Johnson & Johnson Pharmaceuticals, Spectrum Vision Limited Liability Company, SterilMed, Synthes, Synthes GmbH, Synthes Holding AG, Synthes Lux Finance S.àr.l., Synthes Luxembourg, Synthes Produktions GmbH, Synthes USA, Synthes USA Products, TARIS Biomedical, The Anspach Effort, Turnbuckle Investment Company, Vania Expansion, Verb Surgical, Vogue International, XO1, Xian-Janssen Pharmaceutical Ltd., and Zarbee's Naturals.

When was Johnson & Johnson founded?

Johnson & Johnson was founded in 1886.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

Where are Johnson & Johnson's headquarters?

Johnson & Johnson is headquartered at ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 4/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here